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SUMMARY Exfoliative erythroderma refers to the skin that is diffusely red 
and inflamed with varying degrees and types of scaling. There are many 
causes of erythroderma, but the most common are exacerbations of an 
underlying skin disease, drug reactions and underlying malignancies. 
Erythroderma is a rare, potentially serious skin condition. Protein loss 
in the form of desquamation and exudation is significant, resulting in 
hypoproteinemia. Usually more than one skin biopsy should be done. 
Biopsy analysis is important to rule out cutaneous T-cell lymphoma. 
Patients should be carefully evaluated for underlying disease. 
Erythroderma can represent a serious medical threat to the patient, and 
may require hospitalization. Various forms of exfoliative erythroderma 
are presented, considering the etiopathogenesis, physical findings, 
differential diagnosis and treatment.
KEY WORDS: exfoliative erythroderma, exfoliative dermatitis, Sézary 
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INTRODUCTION
 Erythroderma refers to the skin that is diffusely 
red and inflamed with varying degrees and types 
of scaling (1). There are many causes of erythro-
derma, but the most common are exacerbations 
of an underlying skin disease, drug reactions and 
malignancies, primarily mycosis fungoides (MF). 
Usually more than 90% of the skin is involved, but 
residual islands of normal skin may be of great im-
portance in clinical diagnosis. For example, pity-
riasis rubra pilaris (PRP) and MF are character-
ized by such spared areas. The scales may vary 
greatly, coming off in sheets in acute drug induced 
erythroderma, but being smaller or finer in psoria-
sis or PRP. Pruritus is common and often unbear-
able (1).
 Erythroderma can be classified into primary 
and secondary types. In primary erythroderma, 
skin changes arise on the previously normal skin, 
usually as part of malignant lymphoma or of drug 
reactions. In secondary erythroderma, an underly-
ing skin disease is spreading and it involves the 
entire skin (e.g., psoriasis, allergic contact derma-
titis, PRP or lichen ruber planus) (2).
EPIDEMIOLOGY
 Erythroderma is a rare, yet easily recognized, 
potentially serious skin condition. Its reported in-
cidence varies widely, from 1 to 71 per 100,000 
dermatologic outpatients (3-5). Studies in large 
patient series focused on male to female ratio, 
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mean age and underlying diseases (3-11). Men 
are more commonly affected (male to female 
ratio of approximately 2:1 to 4:1) and the mean 
age is between 40 and 60 years (12). Among 746 
patients, the most common underlying causes of 
erythroderma were dermatitis (24%), psoriasis 
(20%), drug reactions (19%) and cutaneous T-cell 
lymphoma (CTCL) accounting for 8% of cases 
(12).
 In 25%-39% of patients, the cause of erythro-
derma remains unknown (idiopathic) and some 
of these patients eventually develop CTCL (13). 
This group consists primarily of elderly men with 
a chronic course of relapsing pruritic erythroder-
ma in association with dermatopathic lymphade-
nopathy and extensive palmoplantar keratoderma 
(13).
PATHOGENESIS
 Erythroderma has profound effects on the en-
tire body. The widespread inflammatory response, 
increased blood flow and marked desquamation 
all take their toll. Vasodilatation and increased 
blood flow lead to chills and impaired temperature 
control. Hypothermia is a possible complication. 
Increased evaporation is possible by increased 
blood flow and damaged epidermal barriers, lead-
ing to dehydration and fluid problems. Protein 
loss in the form of desquamation and exudation 
is significant, resulting in hypoproteinemia. The 
daily loss of scales increases from 500-1000 mg 
to 20-30 g (1,14). Typically, there is hypoalbumin-
emia with a relative increase in immunoglobulins, 
especially γ-globulins. Both hair and nails are in-
fluenced by the increased demands, telogen ef-
fluvium and transverse nail bands are expected. 
Cardiovascular, renal and hepatic complications 
are common (1). Generalized lymphadenopathy 
is found very often (15).
SPECIFIC FINDINGS OF THE 
UNDERLYING DISEASE
 Psorasis
 Psoriatic erythroderma (Fig. 1) is preceded by 
typical psoriatic plaques. Its onset is most often the 
result of a sudden withdrawal of potent topical or 
oral corticosteroids, methotrexate, phototoxicity or 
systemic infection. Nail changes such as oil drops 
changes, onycholysis, or nail pits, may still be vis-
ible and provide valuable clues to the diagnosis of 
psoriatic erythroderma. According to Tomasini et 
al., in a group of patients with a discharge diagno-
sis of psoriatic erythroderma, the histopathologic 
changes were specific for psoriasis in 40 (88%) 
cases (16). 
 Atopic dermatitis 
 Atopic erythroderma (Fig. 2) is most frequent-
ly found in patients with a history of moderate to 
severe atopic dermatitis. The pruritus is intense. 
Increased serum IgE and eosinophilia may be 
accompanied with other signs and symptoms of 
atopy. A constant histologic finding in atopic eryth-
roderma is mild to moderate spongiosis, which is 
sometimes located in the follicular infundibulum. 
Almost always, acanthosis and parakeratosis are 
additional histologic features (12).
 Drug reactions
 The list of drugs that cause exfoliative dermati-
tis is large and continuously growing. Histological-
ly, changes vary considerably. More than 60 drugs 
have been implicated in the causation of erythro-
derma. Among the most commonly implicated are 
pyrazolone derivatives, carbamazepine, hydan-
tion derivatives, cimetidine, lithium salts, and gold 
and gold salts (1).
 Netherton’s syndrome
 Netherton’s syndrome manifests as an eryth-
roderma in neonates. It is associated with trichor-
 
Figure 1. Psoriatic erythroderma.
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rexis invaginata (“bamboo hair“), atopic dermatitis 
and an immune defect that can result in life threat-
ening infections (17).
 Cutaneous T-cell lymphoma
 Erythroderma due to CTCL is subdivided into 
Sézary syndrome and erythrodermic mycosis fun-
goides. Sézary syndrome (Fig. 3) is defined by 
the triad of symptoms: erythroderma, circulating 
malignant T lymphocytes, and generalized lymph-
adenopathy. Additional clinical features include 
painful and fissured keratoderma, diffuse alopecia 
and leonine facies. The skin may be strongly infil-
trated and severe pruritus is common. The mani-
festations of erythrodermic mycosis fungoides 
are clinically identical to Sézary syndrome, but 
leukemic Sézary cells are absent. The histologic 
picture of typical erythrodermic CTCL consists of 
a band-like infiltrate in the papillary dermis con-
taining small to medium sized mononuclear cells 
with hyperchromatic, cerebriform nuclei as well as 
a variable number of inflammatory cells (18).
 Paraneoplastic erythroderma
 Erythroderma can also be a paraneoplastic 
marker for a wide range of hematologic malignan-
cies, and rarely even for other solid tumors. In 
such cases, the onset is more rapid and there is 
no history of precursor lesions. Histologic exami-
nation of the lymph nodes or other tissue is crucial 
because the skin changes are rarely caused by 
infiltrating tumor cells (12).
 Pityriasis rubra pilaris
 Erythrodermic PRP can be observed in children 
and adults. Usually the lesions have a salmon or 
orange-red color. The presence of perifollicular 
keratotic plugs on the knees, elbows and dorsal 
side of the hands, as well as nappes claires (is-
lands of uninvolved skin) within the erythroderma, 
is highly suggestive of PRP. The characteristic 
histologic finding in PRP is orthokeratosis foci al-
ternating with parakeratosis in both vertical and 
horizontal directions (12).
 Omenn’s syndrome 
 Omenn’s syndrome represents an autosomal 
recessive form of severe combined immunodefi-
ciency and is characterized by leukocytosis with 
prominent eosinophilia and increased T/B cell 
ratio, hypogammaglobulinemia and elevated IgE 
levels. Cutaneous findings include exfoliative 
erythroderma with diffuse alopecia (19,20).
DIAGNOSTIC APPROACH
 Clinical recognition of the erythroderma is easy, 
but the diagnosis of the underlying cause may be 
very difficult. The issue is deciding which triggered 
or caused the problem, primary or secondary eryth-
roderma. The existence of previous skin disease 
and how it was treated are crucial. The age of the 
patient also play a role. One must search carefully 
for subtle signs of an underlying disease. Many 
patients have lymphadenopathy which, while usu-
ally reactive or dermatopathic, may reflect an un-
Figure 2. Atopic erythroderma
Figure 3. Sézary syndrome
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derlying lymphoma. If the diagnosis is unclear, a 
lymph node biopsy should be considered.
 Usually more than one skin biopsy should be 
done. Multiple biopsies are usually but not invari-
ably helpful because they may not show any dis-
tinctive histologic features. The biopsy is important 
to rule out CTCL. The patients should be carefully 
evaluated for underlying disease. Lymph node bi-
opsy is advisable if lymphoma is suspected. Use-
ful approaches include chest x-ray, computerized 
tomography of the abdomen, pelvis and thorax, 
routine blood evaluation, iron and folic acid levels, 
immunoelectrophoresis, and bone marrow exami-
nation (1).
TREATMENT
 Erythroderma can pose a serious medical 
threat to the patient and may require hospitaliza-
tion. The patients are more comfortable if they are 
in warm, humid environment. The initial manage-
ment consists of nutritional assessment, correc-
tion of fluid and electrolyte imbalances, preven-
tion of hypothermia, and treatment of secondary 
infections. Sedating oral antihistamines may ease 
the often severe pruritus. Systemic corticosteroids 
may be necessary in idiopathic erythroderma and 
drug reactions. Topical therapy includes open wet 
dressings and bland emollients or low-potency 
corticosteroid ointments. High-potency topical cor-
ticosteroids should be avoided due to increased 
transcutaneous absorption (21).
PROGNOSIS
Drug induced cases have the best prognosis, as 
they have rapid improvement (4,10). Secondary 
erythroderma to underlying skin diseases tends to 
improve over a few weeks, and as many as two-
thirds of patients enter remission (22). Exfoliative 
dermatitis secondary to CTCL and internal malig-
nancies tends to be more persistent (23).
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